Filing Analysis
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reporting period: Quarter ended September 30, 2024.
- Filing date: October 29, 2024.
- The company is classified as an 'emerging growth company'.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Financial results reported are for the quarter ended June 30, 2024.
- The company is classified as an 'emerging growth company'.
- Press release dated July 30, 2024, is attached as Exhibit 99.1.
Nautilus Biotechnology, Inc. held its 2024 annual meeting of stockholders on June 13, 2024. The filing reports the results of shareholder votes regarding the election of Class III directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Total shares outstanding as of record date (April 16, 2024): 125,265,015.
- Shares represented at meeting: 105,300,784 (approx. 84% of outstanding shares).
- Melissa Epperly, Matthew L. Posard, and Karen Akinsanya were elected to the Class III Board of Directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024.
📋 Key Facts
- Report date: April 30, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard earnings release under Item 2.02
- Company is classified as an emerging growth company
Nautilus Biotechnology, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended December 31, 2023.
📋 Key Facts
- Reported financial results for the quarter and fiscal year ended December 31, 2023.
- The filing was made on February 28, 2024.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Nautilus Biotechnology entered into an 'at the market' (ATM) sales agreement with TD Cowen to sell up to $125 million in common stock. This allows the company to raise capital incrementally through a shelf registration statement.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings can create downward pressure on the share price during execution.
📋 Key Facts
- Entered into a Sales Agreement with Cowen and Company, LLC on February 28, 2024.
- Aggregate sales proceeds of up to $125,000,000 in common stock.
- The offering is an 'at the market' (ATM) program under Rule 415.
- TD Cowen will receive compensation of up to 3.0% of gross proceeds.
- Sales are subject to a shelf registration statement on Form S-3 filed on February 28, 2024.